drugset / Trial / NCT04131556

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

NCT04131556

Phase 1 Terminated 20 enrolled Shire
RandomizedCrossoverOpen-labelTreatment

Summary

The Purpose of this study is to assess the relative bioavailability, dose proportionality, the impact of food on the rate and extent of absorption, palatability of the selected pediatric formulation of maribavir and the safety and tolerability of two candidate pediatric formulations and the adult tablet formulation of maribavir in healthy participants.

Timeline

Start
2019-10-25
Primary completion
2020-01-06
Completion
2020-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Maribavir Small molecule 50 mg Oral
Subject Maribavir Small molecule 100 mg Oral
Subject Maribavir Small molecule 200 mg Oral

Indications

No indication recorded.